WINGLORE (Bristol-Myers Squibb Australia Pty Ltd)
Product name
WINGLORE
Date registered
Evaluation commenced
Decision date
Approval time
231 (255 working days)
Active ingredients
Ipilimumab
Registration type
EOI
Indication
Oesophageal Squamous Cell Carcinoma (OSCC)
WINGLORE in combination with nivolumab is indicated for the first-line treatment of patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell PD-L1 expression ≥ 1% as determined by a validated test.